Litigation Details for Sanofi v. Watson Laboratories Inc. (D. Del. 2014)

Sanofi v. Watson Laboratories Inc. (D. Del. 2014)

Docket		Date Filed	2014-02-26
Court	District Court, D. Delaware	Date Terminated	2016-09-22
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Parties	ALKEM LABORATORIES LTD.
Patents	7,323,493; 8,318,800; 8,410,167; 8,602,215
Attorneys	Kenneth Laurence Dorsney
Firms	Phillips, McLaughlin & Hall, P.A.
Link to Docket	External link to docket

Details for Sanofi v. Watson Laboratories Inc. (D. Del. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-02-26				External link to document

Last updated: July 27, 2026

ecutive summary Sanofi’s lawsuit against Watson Laboratories Inc. in case 1:14-cv-00264 centers on patent-based barriers to generic entry. The case is procedurally consistent with US Hatch-Waxman patent litigation in which Sanofi asserted one or more Orange Book-listed patents and Watson sought to market a competing product under a paragraph IV notice. The litigation record available at this request level does not include the specific asserted patent numbers, claims, FDA product, Markman schedule, final judgment dates, or settlement terms. Without those case-defining facts, a complete litigation summary and merits analysis cannot be produced accurately.

Sanofi v. Watson Laboratories Inc. 1:14-cv-00264 litigation summary and patent analysis

What patents did Sanofi assert in Sanofi v. Watson Laboratories Inc. 1:14-cv-00264?

A litigation summary requires the asserted patent list (numbers, expiration dates, and Orange Book mapping) and the specific claim themes (composition, method-of-use, formulation, or manufacturing). This information is not present in the provided input.

Which Orange Book patents were at issue?

Orange Book patents at issue determine:

• whether the case is composition-of-matter versus method-of-use
• whether Watson’s alleged infringement theories are likely to hinge on a narrow claim construction or broad coverage
• the practical “design-around” feasibility for a generic or authorized product

Those Orange Book linkages are not included in the provided input.

What claim types were alleged (composition, method-of-use, formulation)?

Patent claim type drives infringement risk and litigation posture:

• composition claims typically raise issues of structural identity and chemical equivalents
• method-of-use claims often focus on proposed label indications and regimen
• formulation/manufacturing claims typically turn on process control and excipient/process specifics

No claim-type detail is available in the provided input.

What generic or biosimilar entry was targeted by the 1:14-cv-00264 case?

To connect litigation to commercial exposure, the case caption must be tied to:

• the FDA application (ANDA/BLA)
• the reference listed drug (RLD)
• the application number and paragraph IV certification
• the proposed product dosage form and strength

This linkage is not included in the provided input.

Was the case tied to an ANDA paragraph IV notice?

In Hatch-Waxman cases, Sanofi’s standing and the court’s timing depend on paragraph IV notice mechanics and FDA approval timing. No paragraph IV notice details are provided.

What FDA pathway and product profile were in play?

Product profile determines:

• likely design-around strategies
• label carving risks
• whether a generic launch is feasible despite partial invalidity findings

No product profile is available in the provided input.

How did the litigation progress procedurally in 1:14-cv-00264?

A complete litigation analysis normally covers the procedural timeline:

• complaint filing date
• answer and counterclaims (invalidity, non-infringement)
• preliminary injunction briefing (if sought)
• Markman claim construction schedule
• dispositive motions (summary judgment on infringement/invalidity)
• final judgment and post-judgment motions
• appellate history, if any

The provided input does not include docket dates or case events.

Were there Markman rulings that changed infringement risk?

Markman outcomes often determine:

• claim scope
• whether “essential elements” are present in the proposed generic product
• whether a narrower construction enables design-around

No Markman decisions are included in the provided input.

Were any motions for summary judgment decided?

Dispositive motions can collapse the case around:

• statutory subject matter
• anticipation/obviousness grounds
• inequitable conduct or prosecution history estoppel
• non-infringement on claim elements

No motion outcomes are available in the provided input.

What was the infringement and invalidity theory Sanofi used in 1:14-cv-00264?

Litigation analysis requires:

• Sanofi’s claim chart logic
• whether infringement was direct versus induced/contributory
• invalidity bases asserted by Watson (35 USC §§ 102, 103, 112)
• prior art list and technical theory
• expert testimony themes reflected in orders or rulings

No such technical/legal details are present in the provided input.

How did Watson challenge infringement in 1:14-cv-00264?

Generic defenses typically include:

• non-infringement based on structural/process differences
• non-infringement based on absence of functional limitations
• invalidity arguments that would negate claim scope

Those defenses are not described in the provided input.

Which invalidity grounds were asserted (anticipation, obviousness, §112)?

Invalidity grounds determine:

• strength of evidentiary record at trial versus on motion
• speed to settlement versus prolonged merits litigation
• likelihood of appeal

No invalidity grounds are available in the provided input.

When did exclusivity and patent expiry affect the 1:14-cv-00264 litigation timeline?

A business-grade timeline ties:

• patent expiry
• regulatory exclusivity (5-year, 7-year, pediatric extensions, exclusivity for biologics where relevant)
• FDA approval timing
• statutory 30-month stay triggers

The provided input does not include any relevant patent expiry or exclusivity dates.

What are the key patent expiration dates for the Orange Book patents at issue?

No patent numbers or expiration dates are provided.

Did a 30-month stay influence the case posture or settlement pressure?

30-month stay mechanics often determine whether parties settle pre-judgment. No stay information is provided.

How strong was Sanofi’s patent estate in this dispute?

Patent estate strength requires:

• number of asserted patents
• overlapping claim coverage
• remaining term at filing
• history of reexamination, IPR outcomes, or prior adverse rulings
• whether the asserted patents are still enforced against other generics

None of these estate metrics are available in the provided input.

How many asserted patents were in the litigation (and what were their remaining terms at filing)?

Not available.

Were any patents narrower or easier to design around?

Not available.

What Paragraph IV challenges and settlements were involved in 1:14-cv-00264?

For business impact, the record must show:

• whether the case ended via settlement
• whether settlement included a launch date (“carve-out” or agreed entry date)
• whether there were monetary terms
• whether exclusivity was “waived” or “preserved” through covenant language
• whether there was a consent decree or stipulated dismissal after injunction denial

No settlement terms are included in the provided input.

What were the settlement triggers and effective dates?

Not available.

Were there agreed design-around constraints?

Not available.

What is the current status of the case 1:14-cv-00264?

A status report requires:

• the disposition (dismissed, judgment for plaintiff, judgment for defendant)
• date of final judgment
• whether appeal was filed and outcome
• whether the district court judgment is final or stayed pending appeal

No status information is included in the provided input.

How does this litigation compare with other Sanofi vs. generic cases?

Comparison requires:

• therapeutic area and drug identity
• patent profile and typical claim types
• settlement patterns and entry dates across cases

The provided input does not identify the drug, therapeutic area, or drug identity.

Does the outcome pattern match Sanofi’s broader strategy in patent enforcement?

Not available.

How does 1:14-cv-00264 affect generic entry risk and FDA market timing?

Market impact depends on:

• injunction scope (if any)
• covenant language effect on FDA approval/launch
• whether any claims survived and whether the generic launched “at risk”
• whether later appellate or reexamination events changed enforceability

No market-timing or injunction/launch data is provided.

What generic entry risks exist for the relevant molecule/dosage form?

Not available.

What manufacturing and formulation IP barriers remain after this litigation?

Not available.

Key Takeaways

The case caption Sanofi v. Watson Laboratories Inc., 1:14-cv-00264 indicates patent litigation consistent with Hatch-Waxman, but this request does not include the case-defining items needed for an accurate litigation summary and merits analysis, including asserted patents, the FDA product/application at issue, procedural rulings, final disposition, and any settlement terms.

FAQs

1. What Orange Book patents does Sanofi list for the reference product tied to 1:14-cv-00264?
2. Did Watson file a paragraph IV certification, and what were the certification numbers in 1:14-cv-00264?
3. Were any patents in 1:14-cv-00264 subject to IPR or reexamination during the case?
4. Was there a preliminary injunction motion in the 1:14-cv-00264 docket, and what did the court decide?
5. Did the parties reach a settlement with an agreed generic launch date in 1:14-cv-00264?

References

1. Not provided in the input.